Welcome to our dedicated page for Mesoblast SEC filings (Ticker: MEOBF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mesoblast Limited (MEOBF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer incorporated in Australia. Mesoblast Limited files annual reports under cover of Form 20-F and furnishes current information on Form 6-K pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Mesoblast’s Form 6-K submissions typically attach documents first filed with the Australian Securities Exchange (ASX). These include new issue announcements, notifications of issue, conversion or payment up of unquoted equity securities (Appendix 3G), applications for quotation of securities (Appendix 2A), notifications of cessation of securities (Appendix 3H), proposed issues of securities (Appendix 3B), and change of director’s interest notices (Appendix 3Y), as well as press and news release announcements.
Through this page, users can review how Mesoblast Limited reports on equity securities activity, including issuances, proposed issues, cessations, and applications for quotation, and how it discloses changes in directors’ holdings in its securities. These filings are relevant for investors tracking capital structure developments, director share transactions, and formal corporate announcements.
Stock Titan enhances these filings with AI-powered tools that help explain the structure and contents of lengthy documents. While the original Form 20-F and 6-K texts remain the authoritative sources, AI summaries can highlight key sections, such as equity changes or director interest updates, and make it easier to navigate the exhibits attached from the ASX. Real-time updates from EDGAR ensure that new Mesoblast Limited filings appear promptly, giving users a structured way to follow the company’s regulatory history.
Dr. William Gueck reported beneficial ownership of 64,521,900 Ordinary Shares of Mesoblast Ltd held in the form of American Depositary Receipts (ADRs), representing approximately 5.0% of the company's outstanding Ordinary Shares based on 1,281,167,187 shares outstanding. He is the sole beneficial owner of 525,000 ADRs and reports discretionary authority over additional ADRs held by family members, trusts and entities, including 49,717,450 ADRs held by Cova Holdings LP, 350,000 ADRs underlying exercisable warrants held by Cova Holdings LP, and 8,345,150 ADRs held by AVCO Holdings LP. The filing disclaims admission of beneficial ownership of shares held by the identified entities.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information simultaneously released in its home market. On September 15, 2025, the company filed a news release with the Australian Securities Exchange, which is attached to this report as Exhibit 99.1 and incorporated by reference.
Mesoblast Limited, an Australia-based company, submitted a Form 6-K for September 2025 to update U.S. investors about a corporate disclosure made in its home market. On September 12, 2025, the company filed a new issue announcement and a change of director’s interest notice (Appendix 3Y) with the Australian Securities Exchange, and this Appendix 3Y is attached to the Form 6-K as Exhibit 99.1.